Skip to main content
. 2014 Oct 30;6(6):1571–1584. doi: 10.4161/19420862.2014.975660

Figure 5.

Figure 5.

Antitumor activity of MEDI-565 in human tumor xenograft mouse models. (A) Mean tumor volume of Kras and PI3KCA mutant LS174T colon (CEA positive) or HeyA8 ovarian (CEA negative) tumor cells engrafted with human T cells in SCID mice and treated daily with PBS, MEDI-565 or control BiTE® antibody, as indicated (arrows) for 5 days. (B) Activity of MEDI-565 administered by the IV or SC routes of administration in mice engrafted with LS174T cells and human T cells. (C) Mean tumor volume of Kras, BRAF, PI3KCA and/or TP53 mutant tumors (HT-29, H727, HPAC, HPAF II) and wild-type (MKN45) tumors engrafted with human T cells. Error bars represent SEM. Arrows indicate study days when mice were administered test article. *, p < 0.05, Mann-Whitney rank sum test.